TCR2 Therapeutics Inc. reaches new high 1 time this year

Trending News ☀️

TCR2($NASDAQ:TCRR) Therapeutics Inc has had a great year so far, reaching a new high 1 time. As of Friday’s close, the stock was down -$0.17, moving down -7.00 percent to $2.26. Despite this slight dip, the company is still up overall for the year and looks to continue its success in the coming months.

Market Price

TCR2 Therapeutics Inc reached a new high of $2.2 on Monday, but closed at $2.2, down 4.9% from the prior closing price of $2.3. TCR2 Therapeutics is a clinical-stage immunotherapy company that develops novel T cell therapies for cancer and other diseases. The company’s stock has been volatile this year, but Monday’s new high shows that it is still attracting investors.

VI Analysis

The company’s fundamentals reflect its long term potential, and the VI app makes it easy to see how TCR2 Therapeutics stacks up against its peers. According to the VI Star Chart, TCR2 Therapeutics has an intermediate health score of 4/10, which takes into account its cashflows and debt. This indicates that the company is likely to be able to sustain future operations in times of crisis.

However, TCR2 Therapeutics is weak in terms of dividend, growth, and profitability. It is classified as an “elephant” company, which is one that is rich in assets after deducting liabilities. Such companies are deemed to be less risky, as their intrinsic value is pegged to their assets.

Summary

TCR2 Therapeutics Inc is a clinical-stage immuno-oncology company developing novel TCR T cell therapies for the treatment of patients with cancer. The company’s stock price has reached a new high 1 time this year, but has also moved down the same day. Despite this volatility, investors may be attracted to the company’s potential in the immuno-oncology space.